Education
About Us
Working with TipRanks
Follow Us
Vaxxinity Inc (VAXX)
OTHER OTC:VAXX
VAXX Stock Chart & Stats
$0.04
$0.00(0.00%)
At close: 4:00 PM EST
$0.04
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$0.00 - $0.05
Previous CloseN/A
Volume1.04K
Average Volume (3M)5.29K
Market Cap
$42.20K
Enterprise ValueN/A
Total Cash (Recent Filing)$30.39M
Total Debt (Recent Filing)$15.17M
Price to Earnings (P/E)―
Beta272.54
Next Earnings
Apr 01, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.45
Shares Outstanding126,784,680
10 Day Avg. Volume3,116
30 Day Avg. Volume5,294
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)<0.01
Price to Sales (P/S)0.00
P/FCF Ratio>-0.01
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Vaxxinity Inc News
VAXX FAQ
What was Vaxxinity Inc’s price range in the past 12 months?
Vaxxinity Inc lowest stock price was $0.00 and its highest was $0.05 in the past 12 months.
What is Vaxxinity Inc’s market cap?
Vaxxinity Inc’s market cap is $42.20K.
When is Vaxxinity Inc’s upcoming earnings report date?
Vaxxinity Inc’s upcoming earnings report date is Apr 01, 2025 which is 259 days ago.
How were Vaxxinity Inc’s earnings last quarter?
Currently, no data Available
Is Vaxxinity Inc overvalued?
According to Wall Street analysts Vaxxinity Inc’s price is currently Overvalued.
Does Vaxxinity Inc pay dividends?
Vaxxinity Inc does not currently pay dividends.
What is Vaxxinity Inc’s EPS estimate?
Vaxxinity Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Vaxxinity Inc have?
Vaxxinity Inc has 126,784,680 shares outstanding.
What happened to Vaxxinity Inc’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Vaxxinity Inc?
Currently, no hedge funds are holding shares in VAXX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Vaxxinity Inc
Vaxxinity, Inc., a biotechnology company, focuses on developing product candidates for human use in the fields of neurology and coronaviruses in the United States. The company engages in developing UB-311 that targets toxic forms of aggregated amyloid-b in the brain to fight Alzheimer's disease (AD) that is in phase 2 clinical trial; UB-312 that targets toxic forms of aggregated a-synuclein in the brain to fight Parkinson's disease and other synucleinopathies, such as Lewy body dementia and multiple system atrophy that is in phase 1 clinical trial; and an anti-tau product candidate for various neurodegenerative conditions, including AD. It is also developing UB-313 that targets calcitonin gene-related peptide to fight migraines; anti-PCSK9 that targets proprotein convertase subtilisin/kexin type 9 serine protease to lower low-density lipoprotein cholesterol and reduce the risk of cardiac events; and UB-612 for neutralizing the SARS-CoV-2 virus, which is in phase 3 clinical trial. Vaxxinity, Inc. was founded in 2014 and is headquartered in Dallas, Texas.
Technical Analysis
AIM ImmunoTech
―
Scinai Immunotherapeutics
―
Evaxion Biotech
―
GRI Bio
―
Conduit Pharmaceuticals
―
Ownership Overview
―
Insiders
0.06% Mutual Funds
0.02% Other Institutional Investors
99.93% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---